Table 3 Characteristics and outcome according to NIV effectiveness
Success | Failure | ||
|---|---|---|---|
No. of episodes | 23 | 11 | p value |
Age, yr | 26.4 ± 6.9 | 28.8 ± 10.2 | ns |
Sex, M/F | 15/8 | 5/6 | ns |
BMI, Kg/m2 | 17.0 ± 1.5 | 17.9 ± 2.3 | ns |
Lung function in stable state | |||
FEV1, % predicted | 22 ± 5 | 27 ± 8 | 0.02 |
Room air PaO2, mmHg | 54 ± 13 | 58 ± 11 | ns |
Room air PaCO2, mmHg | 52 ± 8 | 47 ± 8 | 0.07 |
Annual FEV1 loss, % predicted/yr | 4.27 ± 2.55 | 4.44 ± 2.39 | ns |
Home NIV | 14 (61%) | 4 (36%) | 0.07 |
Waiting for lung transplant | 8 (35%) | 3 (27%) | ns |
Acute episode characteristics | |||
SAPSII | 21 ± 9 | 28 ± 20 | ns |
PaO2 at entry, mmHg | 60 ± 21 | 66 ± 14 | ns |
PaCO2 at entry, mmHg | 70 ± 19 | 70 ± 24 | ns |
Arterial pH at entry | 7.37 ± 0.06 | 7.35 ± 0.09 | ns |
Admission for pulmonary exacerbation | 19 (83%) | 10 (91%) | ns |
Length of NIV, days | 9.1 ± 6.8 | 3.8 ± 3.9 | 0.02 |
Length of ICU stay, days | 9.1 ± 6.8 | 8.6 ± 9.5 | ns |
ICU mortality, number of patients (%) | 0 (0%) | 8 (73%) | <0.001 |